CN104968364A - 强化免疫调变性Fc融合蛋白的抗癌活性 - Google Patents

强化免疫调变性Fc融合蛋白的抗癌活性 Download PDF

Info

Publication number
CN104968364A
CN104968364A CN201380072031.1A CN201380072031A CN104968364A CN 104968364 A CN104968364 A CN 104968364A CN 201380072031 A CN201380072031 A CN 201380072031A CN 104968364 A CN104968364 A CN 104968364A
Authority
CN
China
Prior art keywords
ctla
antibody
tumor
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380072031.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·J·恩格尔哈特
A·J·科曼
M·奎格利
M·J·塞尔比
C·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49877017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104968364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CN202310218856.5A priority Critical patent/CN116637183A/zh
Publication of CN104968364A publication Critical patent/CN104968364A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380072031.1A 2012-12-03 2013-12-03 强化免疫调变性Fc融合蛋白的抗癌活性 Pending CN104968364A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310218856.5A CN116637183A (zh) 2012-12-03 2013-12-03 强化免疫调变性Fc融合蛋白的抗癌活性

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261732760P 2012-12-03 2012-12-03
US61/732,760 2012-12-03
US201361801187P 2013-03-15 2013-03-15
US61/801,187 2013-03-15
PCT/US2013/072918 WO2014089113A1 (en) 2012-12-03 2013-12-03 Enhancing anti-cancer activity of immunomodulatory fc fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310218856.5A Division CN116637183A (zh) 2012-12-03 2013-12-03 强化免疫调变性Fc融合蛋白的抗癌活性

Publications (1)

Publication Number Publication Date
CN104968364A true CN104968364A (zh) 2015-10-07

Family

ID=49877017

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380072031.1A Pending CN104968364A (zh) 2012-12-03 2013-12-03 强化免疫调变性Fc融合蛋白的抗癌活性
CN202310218856.5A Pending CN116637183A (zh) 2012-12-03 2013-12-03 强化免疫调变性Fc融合蛋白的抗癌活性

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310218856.5A Pending CN116637183A (zh) 2012-12-03 2013-12-03 强化免疫调变性Fc融合蛋白的抗癌活性

Country Status (16)

Country Link
US (5) US20150322119A1 (2)
EP (2) EP3508215A3 (2)
JP (4) JP2016500251A (2)
CN (2) CN104968364A (2)
CY (1) CY1121557T1 (2)
DK (1) DK2925350T3 (2)
ES (1) ES2715673T3 (2)
HR (1) HRP20190574T1 (2)
HU (1) HUE043903T2 (2)
LT (1) LT2925350T (2)
PL (1) PL2925350T3 (2)
PT (1) PT2925350T (2)
RS (1) RS58528B1 (2)
SI (1) SI2925350T1 (2)
SM (1) SMT201900242T1 (2)
WO (1) WO2014089113A1 (2)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109153727A (zh) * 2016-04-15 2019-01-04 酵活有限公司 靶向免疫治疗剂的多特异性抗原结合构建体
CN110088126A (zh) * 2016-04-15 2019-08-02 高山免疫科学股份有限公司 Icos配体变体免疫调节蛋白及其用途
CN110536693A (zh) * 2017-01-05 2019-12-03 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
CN111902423A (zh) * 2018-01-18 2020-11-06 皮埃蒙特阿米阿伏伽德罗东方大学 基于b7h受体的配体的抗肿瘤治疗剂
CN112739377A (zh) * 2018-07-12 2021-04-30 F星贝塔有限公司 包含cd137抗原结合位点的fc结合片段
CN114729043A (zh) * 2019-09-19 2022-07-08 百时美施贵宝公司 在酸性pH下结合至VISTA的抗体
US11897937B2 (en) 2017-01-05 2024-02-13 Kahr Medical Ltd. SIRPalpha-41BBL fusion protein and methods of use thereof
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
US12173069B2 (en) 2018-03-21 2024-12-24 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
WO2025002321A1 (zh) * 2023-06-30 2025-01-02 凯米生物医药(成都)有限公司 经糖基修饰的融合蛋白、核酸分子、表达载体、宿主细胞及应用
US12187798B2 (en) 2016-06-20 2025-01-07 Invox Pharma Limited LAG-3 binding members
US12195535B2 (en) 2017-03-14 2025-01-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
US12247074B2 (en) 2018-07-12 2025-03-11 Invox Pharma Limited Antibody molecules
US12252537B2 (en) 2018-07-12 2025-03-18 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
US12286466B2 (en) 2018-07-11 2025-04-29 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
US12297283B2 (en) 2018-07-12 2025-05-13 Invox Pharma Limited Fc binding fragments comprising an OX40 antigen-binding site
US12319739B2 (en) 2018-07-12 2025-06-03 Invox Pharma Limited Mesothelin and CD137 binding molecules
US12325742B2 (en) 2018-07-12 2025-06-10 Invox Pharma Limited Anti-mesothelin antibodies
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
US12534534B2 (en) 2018-07-12 2026-01-27 Invox Pharma Limited Anti-CD137 antibodies

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
CN118440206A (zh) 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
SG11201700258VA (en) * 2014-07-16 2017-02-27 Genentech Inc Methods of treating cancer using tigit inhibitors and anti-cancer agents
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR20170072343A (ko) * 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
CN107207594B (zh) * 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
BR112017016681A2 (pt) * 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
CA2988115A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
HK1251474A1 (zh) * 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
KR20180011839A (ko) * 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
EP3307778A1 (en) 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
AU2016297249B2 (en) * 2015-07-23 2020-11-12 Inhibrx Biosciences, Inc. Multivalent and multispecific GITR-binding fusion proteins
EP3331917A1 (en) * 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3334757A4 (en) 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
FI3389699T3 (fi) * 2015-12-15 2024-05-28 Oncoc4 Inc Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
JP2019512271A (ja) 2016-03-21 2019-05-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
FR3051794A1 (fr) * 2016-05-31 2017-12-01 Lab Francais Du Fractionnement Anticorps pour le traitement de cancers
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
MX2019004775A (es) 2016-11-03 2019-08-05 Squibb Bristol Myers Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
CN110366565A (zh) 2017-02-28 2019-10-22 百时美施贵宝公司 具有增强的adcc的抗ctla-4抗体增强对疫苗的免疫应答的用途
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019008375A1 (en) * 2017-07-06 2019-01-10 Ucl Business Plc Method for identifying responders to cancer treatment
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
US11512129B2 (en) 2017-09-29 2022-11-29 Jiangsu Hengrui Medicine Co., Ltd. TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
SMT202600062T1 (it) 2017-10-18 2026-03-09 Alpine Immune Sciences Inc Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
TWI816729B (zh) 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
JP7490923B2 (ja) * 2018-02-02 2024-05-28 オンコシーフォー、インク． 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
AU2019216228A1 (en) * 2018-02-02 2020-08-13 Children's Research Institute, Children's National Medical Center Methods of selecting and designing safer and more effective anti-CTLA-4 antibodies for cancer therapy
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
JP2021534216A (ja) * 2018-08-29 2021-12-09 中央研究院Academia Sinica 癌治療のためのシクロホスファミド化合物を有するナチュラルキラー細胞の組み合わせ
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
AU2019413366B2 (en) * 2018-12-27 2025-06-05 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
EP3937979A4 (en) 2019-03-13 2023-03-08 Merck Sharp & Dohme LLC COMBINATIONAL ANTI-CANCER THERAPIES WITH CTLA-4 AND PD-1 BLOCKING AGENTS
BR112022009631A2 (pt) 2019-12-19 2022-08-09 Bristol Myers Squibb Co Combinações de inibidores de dgk e antagonistas do ponto de checagem
KR20220154140A (ko) 2020-03-13 2022-11-21 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pvrig 결합 단백질 및 이의 의학적 용도
PE20230682A1 (es) * 2020-04-17 2023-04-21 Hutchison Medipharma Ltd Anticuerpo anti-ox40 y usos del mismo
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
CA3184082A1 (en) * 2020-07-02 2022-01-06 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof
CN121668303A (zh) 2020-10-11 2026-03-17 百奥泰生物制药股份有限公司 抗pd-1抗体在联合用药中的应用
WO2022098952A1 (en) 2020-11-06 2022-05-12 Bristol-Myers Squibb Company Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
JP2024535793A (ja) 2021-09-15 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用
CN117858903A (zh) 2021-09-15 2024-04-09 江苏恒瑞医药股份有限公司 一种含抗pvrig/tigit双特异性抗体的药物组合物
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
US20260042840A1 (en) 2022-04-07 2026-02-12 Bristol-Myers Squibb Company Methods of treating tumor
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
US20260048119A1 (en) 2022-08-05 2026-02-19 Bristol-Myers Squibb Company Anti-ctla4 antibodies for treatment of kras mutant cancers
CN120693178A (zh) 2023-03-15 2025-09-23 上海迈晋生物医药科技有限公司 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
TW202600608A (zh) 2024-02-27 2026-01-01 美商必治妥美雅史谷比公司 抗ｃｅａｃａｍ５抗體及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133822A1 (en) * 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
CN101484470A (zh) * 2005-10-21 2009-07-15 Gtc生物治疗有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
CN101861168A (zh) * 2007-05-07 2010-10-13 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US20060034844A1 (en) * 1996-12-04 2006-02-16 The Regents Of The University Of California Stimulation of T cells against self antigens using CTLA-4 blocking agents
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
EP2277542B1 (en) * 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
AU2004215133B2 (en) * 2003-02-27 2010-10-14 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
BRPI0607796A2 (pt) 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2007056540A2 (en) 2005-11-08 2007-05-18 Medarex, Inc. Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
ES2396569T3 (es) 2006-01-17 2013-02-22 Medarex, Inc. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
DK2851374T3 (en) 2007-12-14 2017-06-19 Bristol Myers Squibb Co Binding molecules to the human OX40 receptor
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8614295B2 (en) 2009-02-17 2013-12-24 Ucb Pharma S.A. Antibody molecules having specificity for human OX40
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
SMT201700185T1 (it) 2010-08-23 2017-05-08 Univ Texas Anticorpi anti-ox40 e metodi di uso degli stessi
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
EP3682896A1 (en) * 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
AP2014007415A0 (en) 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
CA2845810C (en) 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AU2013222185B2 (en) * 2012-02-23 2018-07-26 Sloan-Kettering Institute For Cancer Research Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484470A (zh) * 2005-10-21 2009-07-15 Gtc生物治疗有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
WO2007133822A1 (en) * 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
CN101861168A (zh) * 2007-05-07 2010-10-13 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEIRDRE O’MAHONY等: "A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy", 《CLIN CANCER RES》 *
WEI LIN等: "Fc-dependent expression of CD137 on human NK cells: insights into "agonistic"effects of anti-CD137 monoclonal antibodies", 《BLOOD》 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110088126A (zh) * 2016-04-15 2019-08-02 高山免疫科学股份有限公司 Icos配体变体免疫调节蛋白及其用途
CN109153727A (zh) * 2016-04-15 2019-01-04 酵活有限公司 靶向免疫治疗剂的多特异性抗原结合构建体
US12187798B2 (en) 2016-06-20 2025-01-07 Invox Pharma Limited LAG-3 binding members
CN110536693A (zh) * 2017-01-05 2019-12-03 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US12331098B2 (en) 2017-01-05 2025-06-17 Kahr Medical Ltd. SIRPalpha-41BBL fusion protein and methods of use thereof
US11702458B2 (en) 2017-01-05 2023-07-18 Kahr Medical Ltd. PD1-41BBL fusion protein and methods of use thereof
CN110536693B (zh) * 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11897937B2 (en) 2017-01-05 2024-02-13 Kahr Medical Ltd. SIRPalpha-41BBL fusion protein and methods of use thereof
US12195535B2 (en) 2017-03-14 2025-01-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
CN111902423A (zh) * 2018-01-18 2020-11-06 皮埃蒙特阿米阿伏伽德罗东方大学 基于b7h受体的配体的抗肿瘤治疗剂
US12173069B2 (en) 2018-03-21 2024-12-24 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
US12286466B2 (en) 2018-07-11 2025-04-29 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
US12297283B2 (en) 2018-07-12 2025-05-13 Invox Pharma Limited Fc binding fragments comprising an OX40 antigen-binding site
US12247074B2 (en) 2018-07-12 2025-03-11 Invox Pharma Limited Antibody molecules
US12252537B2 (en) 2018-07-12 2025-03-18 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
US12103976B2 (en) 2018-07-12 2024-10-01 Invox Pharma Limited Fc binding fragments comprising a CD137 antigen-binding site
US12319739B2 (en) 2018-07-12 2025-06-03 Invox Pharma Limited Mesothelin and CD137 binding molecules
US12325742B2 (en) 2018-07-12 2025-06-10 Invox Pharma Limited Anti-mesothelin antibodies
CN112739377A (zh) * 2018-07-12 2021-04-30 F星贝塔有限公司 包含cd137抗原结合位点的fc结合片段
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
US12534534B2 (en) 2018-07-12 2026-01-27 Invox Pharma Limited Anti-CD137 antibodies
CN114729043A (zh) * 2019-09-19 2022-07-08 百时美施贵宝公司 在酸性pH下结合至VISTA的抗体
WO2025002321A1 (zh) * 2023-06-30 2025-01-02 凯米生物医药(成都)有限公司 经糖基修饰的融合蛋白、核酸分子、表达载体、宿主细胞及应用

Also Published As

Publication number Publication date
US20200207816A1 (en) 2020-07-02
US20230287064A1 (en) 2023-09-14
US20250236650A1 (en) 2025-07-24
JP2019073534A (ja) 2019-05-16
PT2925350T (pt) 2019-03-25
US20150322119A1 (en) 2015-11-12
JP2023078356A (ja) 2023-06-06
PL2925350T3 (pl) 2019-07-31
CN116637183A (zh) 2023-08-25
HUE043903T2 (hu) 2019-09-30
SI2925350T1 (sl) 2019-04-30
EP3508215A2 (en) 2019-07-10
LT2925350T (lt) 2019-04-10
JP7132858B2 (ja) 2022-09-07
CY1121557T1 (el) 2020-05-29
ES2715673T3 (es) 2019-06-05
EP2925350A1 (en) 2015-10-07
EP2925350B1 (en) 2019-01-30
DK2925350T3 (da) 2019-05-13
WO2014089113A1 (en) 2014-06-12
JP2016500251A (ja) 2016-01-12
EP3508215A3 (en) 2019-10-02
RS58528B1 (sr) 2019-04-30
SMT201900242T1 (it) 2019-05-10
JP2021113197A (ja) 2021-08-05
US20180312553A1 (en) 2018-11-01
HRP20190574T1 (hr) 2019-05-17

Similar Documents

Publication Publication Date Title
US20250236650A1 (en) Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
US20220127363A1 (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
EP3955960B1 (en) Ipilimumab variants with enhanced specificity for binding at low ph
US10196445B1 (en) Ipilimumab variant with enhanced ADCC
TWI707872B (zh) 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
TW202202521A (zh) 用於治療癌症之抗ccr8抗體
JP2019510733A (ja) キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
CN116898963A (zh) 治疗癌症的联合疗法
CN111465618A (zh) 双特异性cd16-结合分子及其在疾病治疗中的用途
EP4196502A1 (en) Methods of redirecting of il-2 to target cells of interest

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151007

RJ01 Rejection of invention patent application after publication